Are These Biotech Stocks Ready to Fly?

NakedValue.com issued a list of six biotech stocks poised to make a move.  Let’s take a close look at them and see if they have place in anyone’s portfolio.

  • Denredon Corp. (NASDAQ:DNDN): The shares recently traded at $37.71, and have traded in a 52-week range of $25.78 to $43.96.  Its market capitalization is $5.5 billion and it lost $3 per share last year.  Its forward price to earnings ratio is 209.56, its PEG ratio is -55.07, its price to sales is 73.07, and its price to book is 10.77.  11.7% of the company’s float is sold short, which equals about 16.16 million shares, and which is compared to 16.85 million shares held short in the previous month.  About the company:  Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body’s key defense against cancer. Competitors to Watch: Novartis AG (NYSE:NVS), SuperGen, Inc. (NASDAQ:SUPG), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Genzyme Corporation (NASDAQ:GENZ), Cell Therapeutics, Inc. (NASDAQ:CTIC), Merck & Co., Inc. (NYSE:MRK), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Sanofi-Aventis SA (NYSE:SNY).

Must Read: Jump Ahead in June with Top Insights and Winning Trade Ideas>>

  • AstraZeneca PLC (NYSE:AZN): The shares most recently traded at $49.15 and have traded in a 52-week range of $44.17 to $53.53.  Its market capitalization is $68 billion its P/E ratio is 8.6, it earned $5.70 last year, and it pays a dividend of $3.70 per share.  Its forward P/E ratio is 8.1, its PEG ratio is 3.1, its price to sales ratio is 2.07,  and its price to book ratio is 2.03.  About the company:  AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.  Competitors include: GlaxoSmithKline plc (NYSE:GSK), Brisol Myers Squibb (NYSE:BMY), Pfizer, Inc. (NYSE:PFE), Sanofi-Aventis SA (NYSE:SNY), Merck & Co. (NYSE:MRK), Par Pharmaceutical (NYSE:PRX), and Teva Pharmaceutical (NASDAQ:TEVA).
  • Gilead Sciences Inc. (NASDAQ:GILD): The shares most recently traded at $39.60 and have traded in a 52-week range of $31.73 to $42.93.  Its market capitalization is $31.17 billion, its P/E ratio is 12.41, and it earned $3.19 per share last year.  Its forward P/E is 8.74, its PEG is 0.64, its price to sales is 3.99, and its price to book is 5.26.  About the company:  Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Eli Lilly & Co. (NYSE:LLY), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS) and Sanofi-Aventis (NYSE:SNY).
  • Life Technologies Corp. (NASDAQ:LIFE): The shares most recently traded at $52.12 and have traded in a 52-week range of $41.1 to $57.25.  Its market capitalization is $9.43 billion, its trailing P/E is 25.97, and it earned $2.01 per share last year.  Its forward P/E is 12.06, its PEG ratio is 1.2, its price to sales is 2.57, and its price to book is 2.12.  About the company: Life Technologies Corporation develops biotechnology tools used by researchers. The Company offers a broad range of products and services, including systems, instruments, reagents, and custom services. Life’s portfolio of products includes technologies for capillary electrophoresis based sequencing, sequencing, mass spectrometry sample preparation, and cell culture. Competitors to Watch: Techne Corporation (NASDAQ:TECH), Qiagen NV (NASDAQ:QGEN), Affymetrix, Inc. (NASDAQ:AFFX), Sigma-Aldrich Corporation (NASDAQ:SIAL), Thermo Fisher Scientific Inc. (NYSE:TMO), Strategic Diagnostics Inc. (NASDAQ:SDIX), Agilent Technologies Inc. (NYSE:A), Bio-Rad Laboratories, Inc. (NYSE:BIO), PerkinElmer, Inc. (NYSE:PKI), and Johnson & Johnson (NYSE:JNJ).
  • Seattle Genetics Inc (NASDAQ:SGEN): The shares have recently traded at $20.26, and have traded in a 52-week range of $11.27 to $20.29.  Its market capitalization is $2.31 billion and it lost $1.07 per share last year.  Its PEG ratio is 2.13, its price to sales ratio is 30.31, and its price to book is 7.26. About the company:  Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company’s technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer. Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Biogen Idec Inc. (NASDAQ:BIIB), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Genzyme Corporation (NASDAQ:GENZ), Micromet Inc. (NASDAQ:MITI), Allos Therapeutics, Inc. (NASDAQ:ALTH), Cephalon, Inc. (NASDAQ:CEPH), Celgene Corporation (NASDAQ:CELG), Merck (NYSE:MRK) and ImmunoGen, Inc. (NASDAQ:IMGN)
  • Optimer Pharmaceuticals (NASDAQ:OPTR): The shares have recently traded at $12.53 and have traded in a 52-week range of $7.68 to $14.74.  Its market capitalization is $580.75 million, its P/E ratio is 43.66, and it earned $0.29 per share.  About the company:Optimer Pharmaceuticals, Inc. discovers, develops, and commercializes anti infective products. Optimer’s initial development efforts address products that treat gastrointestinal infections (GI), and related diseases, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance, and bacterial resistance.

Must Read: Jump Ahead in June with Top Insights and Winning Trade Ideas>>

More from The Cheat Sheet